Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Boosted by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. grew its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 1.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 425,419 shares of the biopharmaceutical company’s stock after buying an additional 7,204 shares during the quarter. Envestnet Asset Management Inc. owned about 0.14% of Amicus Therapeutics worth $4,007,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Amicus Therapeutics by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company’s stock valued at $275,619,000 after acquiring an additional 458,143 shares during the last quarter. Wellington Management Group LLP lifted its stake in Amicus Therapeutics by 18.8% during the fourth quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company’s stock valued at $268,112,000 after purchasing an additional 4,497,950 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Amicus Therapeutics by 3.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,267,375 shares of the biopharmaceutical company’s stock worth $30,779,000 after buying an additional 107,348 shares in the last quarter. Norges Bank acquired a new position in Amicus Therapeutics in the fourth quarter worth approximately $29,033,000. Finally, Rice Hall James & Associates LLC increased its holdings in shares of Amicus Therapeutics by 41.0% in the fourth quarter. Rice Hall James & Associates LLC now owns 1,371,080 shares of the biopharmaceutical company’s stock valued at $12,916,000 after buying an additional 398,942 shares in the last quarter.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on FOLD shares. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Wells Fargo & Company cut their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, February 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $16.75.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD opened at $7.09 on Thursday. The firm has a market cap of $2.18 billion, a price-to-earnings ratio of -39.37, a P/E/G ratio of 1.51 and a beta of 0.79. Amicus Therapeutics, Inc. has a 1 year low of $6.20 and a 1 year high of $12.65. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The business has a fifty day simple moving average of $8.26 and a 200 day simple moving average of $9.44.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.